Duarte, California
Cancer biologic therapy trials in Duarte, CA
77 cancer biologic therapy studies are recruiting participants at sites in Duarte as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Duarte at a glance
- 77 studies are recruiting at a site in Duarte.
- By phase: Early Phase 1 (2), Phase 1 (29), Phase 1/2 (7), Phase 2 (25), Phase 2/3 (2), Phase 3 (11), Phase 4 (1).
- By sponsor: university, hospital or other (45), industry (21), government (11).
- By research area: Lymphoma (53), Breast Cancer (9), Lung Cancer (8), Melanoma (3), Prostate Cancer (3), Pancreatic Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Duarte
Basic details from each study's public record (the 30 most recently updated of 77). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- City of Hope ( Site 0097)
- Registry record
- NCT06841354 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT06058377 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Duarte, CA on ClinicalTrials.gov.
Lung cancer studies recruiting in Duarte
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT06287775 · updated
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- City of Hope /ID# 243157
- Registry record
- NCT04928846 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Duarte, CA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Duarte
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT05805371 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Duarte, CA on ClinicalTrials.gov.
Melanoma studies recruiting in Duarte
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- City of Hope National Medical Center
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Duarte, CA on ClinicalTrials.gov.
Lymphoma studies recruiting in Duarte
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT03739814 · updated
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT05272384 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT06337318 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- City of Hope Comprehensive Cancer Center ( Site 0191)
- Registry record
- NCT06890884 · updated
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- City of Hope - Duarte Cancer Center ( Site 1301)
- Registry record
- NCT07634471 · updated
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT07758673 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT05675410 · updated
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT07003295 · updated
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT07275216 · updated
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- PeproMene Bio, Inc.
- Study site
- City of Hope Medical Center
- Registry record
- NCT05370430 · updated
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT07278856 · updated
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT06922604 · updated
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT07582159 · updated
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT06054776 · updated
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- Phase 1
- Ages 18 to 70
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT06287944 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study site
- City of Hope
- Registry record
- NCT06500273 · updated
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT07583810 · updated
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT05890352 · updated
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- Phase 1/2
- Ages 18 to 80
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT05861050 · updated
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT06015880 · updated
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Phase 1/2
- Ages 13 to 90
- All sexes
- Sponsor
- Vironexis Biotherapeutics Inc.
- Study site
- City of Hope
- Registry record
- NCT06533579 · updated
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- City of Hope Medical Center
- Study site
- City of Hope Medical Center
- Registry record
- NCT06059391 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Duarte, CA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Duarte
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- City of Hope Comprehensive Cancer Center
- Registry record
- NCT05372614 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Duarte, CA on ClinicalTrials.gov.
Ask about studies near Duarte
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in California
All California locations
185 studies recruiting across 108 cities.
Los Angeles
73 studies recruiting.
San Francisco
37 studies recruiting.
Sacramento
36 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections